| Autor: |
Penichet ML; Department of Microbiology and Molecular Genetics, and the Molecular Biology Institute, University of Califorina, Los Angeles, 405 Hilgard Avenue, Los Angeles, CA 90095-1489, USA., Dela Cruz JS, Shin SU, Morrison SL |
| Jazyk: |
angličtina |
| Zdroj: |
Human antibodies [Hum Antibodies] 2001; Vol. 10 (1), pp. 43-9. |
| Abstrakt: |
Anti-HER2/neu therapy of human HER2/neu expressing malignancies such as breast cancer has shown only partial success in clinical trials. To expand the clinical potential of this approach, we have genetically engineered an anti-HER2/neu human IgG3 fusion protein containing interleukin-2 (IL-2) fused at its carboxyl terminus. Anti-Her2/neu IgG3-(IL-2) retained antibody and cytokine related activity. Treatment of immunocompentent mice with this antibody fusion protein resulted in significant retardation in the subcutaneous (s.c.) growth of CT26-HER2/neu tumors suggesting that anti-HER2/neu IgG3-(IL-2) fusion protein will be useful in the treatment of HER2/neu expressing tumors. We also found that fusing IL-2 to human IgG3 results in a significant enhancement of the murine anti-human antibody (MAHA) response. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
